A combined approach to assess the potential coverage of a multicomponent protein-based vaccine

Journal of Preventive Medicine and Hygiene

Volumn 53, Issue 2, 2012, Pages 56-60

  Boccadifuoco, G ^a   Brunelli, B ^a   Pizza, M G ^a   Giuliani, M M ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Correlates of protection; ELISA; Neisseria meningitidis

Indexed keywords

4CMENB VACCINE; BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIGENIC VARIATION; BACTERIAL GENETICS; DRUG SCREENING; DRUG TOLERABILITY; EUROPE; GENETIC VARIABILITY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INFECTION PREVENTION; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; MENINGOCOCCOSIS; NONHUMAN; REVIEW;

HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 84864663938     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Claus H, Maiden MC, Wilson DJ, et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis 2005;191:1263-71.
2. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:853-61.
3. Caugant DA, Maiden MC. Meningococcal carriage and disease-population biology and evolution. Vaccine 2009;27 Suppl 2:B64-70.
4. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31: 3-14. (Pubitemid 46058815)
5. Stephens DS. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet Infect Dis 2007;369:2196-10. (Pubitemid 46977462)
6. Bai X, Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines 2010;9:1203-17.
7. Pace D. Quadrivalent meningococcal ACWY-135 glycoconjugate vaccine for broader protection from infancy. Expert Rev Vaccines 2009;8:529-42.
8. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalentb meningococcal glycoconjugate vaccine in Infants: a randomized controlled trial. JAMA 2008;299:173-84.
9. Khatami A, Pollard Aj. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010;9:285-98.
10. Lucidarme J, Comanducci M, Findlow J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010;7:919-29.
11. th Meeting 2011 Ljubljana, Slovenia, Programme and Abstracts book: p. 3.
12. Feavers I. Choosing isolates for the evaluation of meningococcal protein vaccines. Expert Rev Vaccines 2009;8:1461-13.
13. Finne J, Bitter-Suermann D, Goridis C, et al. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987;139:4402-7. (Pubitemid 17090418)
14. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821-9.
15. Fredriksen JH, Rosenqvist E, Wedege E, et al. Production , charachterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. Norwegian Institute of Public Health Ann 1991;14:67-79; discussion 79-80.
16. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neissseria meningitidis: protection trial and mass vaccination results in Cuba. Norwegian Institute of Public Health Ann 1991;14:195-207; discussion 208-10.
17. Oster P, Lennon D, O'hallahan J, et al. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23:2191-6. (Pubitemid 40341449)
18. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicle vaccine from Neisseria meningitidis. Vaccine 2009;27S:B3-B12.
19. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001;19:2688-91. (Pubitemid 32234290)
20. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by wholegenome sequencing. Science 2000;287:1816-20.
21. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003;197:789-99. (Pubitemid 36350873)
22. Seib KL, Serruto D, Oriente F, et al. Factor H binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009;77:292-9.
23. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006;177:501-10. (Pubitemid 43939163)
24. Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010;107:3770-5.
25. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195:1445-54. (Pubitemid 34602821)
26. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-9. (Pubitemid 44148381)
27. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010;29:e71-79.
28. Findlow J, Borrow R, Snape MD, et al. Multicentre, open-label randomised phase II controlled study of an investigational recombinant serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37.
29. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report Emory University, Atlanta, georgia, United States, 16-17 March 2005. Vaccine 2006;24:5093-107. (Pubitemid 44209069)
30. Brunelli B, Del Tordello E, Palumbo E, et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 2011;29:1072-81.
31. Giuliani MM, Biolchi A, Serruto D, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010;28:5023-30.
32. Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadri-valent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011;18:483-6.
33. Toneatto D, Oster P, Deboer AC, et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccine 2011;7:781-91.
34. Gossger N, Snape MD, Yu LM, Finn A, et al. European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307:573-82
35. Santolaya ME, O'Ryan ML, Valenzuela MT et al. V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617-24.
36. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107:19490-5.
37. Vermont C, van den Dobbelsteen G. Neisseria meningitidis serogroup B: laboratory correlates of protection FEMS Immunology and Medical Microbiology 2002;34:89-96.